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Abstract: Carbothioamides 4a,b, obtained from nalidixic 
acid, were converted to the corresponding 1,3-thiazoli-
dine derivatives 5a,b by cyclocondensation with 2-bromo-
1-(4-chlorophenyl)ethanone. Treatment of 4a,b with base 
afforded 1,2,4-triazoles 6a,b. The synthesis of 1,3-oxazo-
lidine 7 was performed by the reaction of compound 4a 
with ethyl bromoacetate. Treatment of 4a with acid pro-
duced 1,3,4-thiadiazole 8. The reaction of compounds 6a 
and 6b with several heterocyclic amines in the presence of 
formaldehyde gave the corresponding Mannich bases 9–15 
containing various pharmacophore groups. Conventional 
and microwave-assisted methods were used for the synthe-
sis. The effect of an acid catalyst on Mannich reactions was 
investigated. The structures of the newly synthesized com-
pounds were elucidated on the basis of 1H NMR, 13C NMR, 
FTIR, EIMS techniques, and elemental analysis. All com-
pounds were screened for their antimicrobial activity.
Keywords: 1,2,4-triazole; antimicrobial activity; Mannich 
base; nalidixic acid; norfloxacin.
Introduction
Nalidixic acid [1-ethyl-7-methyl-4-oxo-1,4-dihydro-
1,8-naphthyridine-3-carboxylic acid, 1] was the first 
synthetic quinolone derivative introduced for the treat-
ment of urinary tract infections in 1963 [1]. It inhibits 
DNA synthesis by promoting cleavage of bacterial DNA in 
the DNA-enzyme complexes of DNA gyrase, resulting in 
rapid bacterial death [2]. It is particularly effective against 
Gram-negative bacteria [3, 4]. Since the introduction of 
nalidixic acid for the treatment of bacterial infections, 
a number of derivatives have been synthesized. Among 
them, fluoroquinolones such as norfloxacin, pefloxa-
cin, enoxacin, ofloxacin, and ciprofloxacin play a major 
role in the treatment of bacterial infections by displaying 
excellent pharmacokinetic properties, high antimicrobial 
activity, and low side effects [5–9]. Quinolones have been 
reported to have wide-ranging biological activities includ-
ing antitubercular [10], fungicidal [11], antimalarial [12], 
anticancer and anti-HIV [12], antiviral [13], and antibacte-
rial [14] properties.
The considerable biological importance of triazoles 
has stimulated a lot of interest in their derivatives [15]. 
A large number of 1,2,4-triazoles exhibit antibacterial, 
antifungal, antitubercular, analgesic, antiinflammatory, 
anticancer, anticonvulsant, antiviral, insecticidal, antide-
pressant, and central nervous system-affecting activities. 
1,2,4-Triazoles, by virtue of their ambident nucleophilic 
centers, are good starting materials for the synthesis of 
several interesting N- and S-bridged heterocycles. The tria-
zoles can be converted to thiazolotriazoles, triazolothiadi-
azoles, triazolooxazolidines, and various Mannich bases 
[16–20]. In addition, a 1,3,4-thiadiazole system constitutes 
the active part of several biologically active compounds 
[21–24]. A thiazolidinone ring is an attractive target for 
combinatorial synthesis as its structure-activity relation-
ship belongs to an important class of N- and S-containing 
heterocycles, which are widely used in drug design and 
synthesis [25, 26]. Related oxazolidinones are also biologi-
cally active [27–30].
In this paper, we report the synthesis of new hybrid 
compounds which are derivatives of the systems men-
tioned above and possess an interesting profile of anti-
microbial activity. The synthetic work was enhanced by 
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using Mannich reaction [31], homogeneous catalysis [32], 
and eco-friendly microwave irradiation [33].
Results and discussion
Chemistry
The main aim of this study was to synthesize antimicrobial 
hybrid molecules containing different heterocyclic moie-
ties. The synthetic strategies adopted to obtain the target 
compounds are depicted in Schemes 1–3. The synthesis 
was achieved by using both microwave (eco-friendly) and 
conventional methods. The structures of all products were 
established on the basis of physicochemical, spectral, and 
elemental analysis data.
The esterification of nalidixic acid (1) with ethanol 
in the presence of a catalytic amount of sulfuric acid fur-
nished ester 2. Then, compound 2 was converted to the 
acetohydrazide 3 by treatment with hydrazine hydrate. 
Synthesis of 3 required 20–22  h of heating under reflux 
conditions and the yield was 75–78%. Under microwave 
irradiation at 100°C for 15 min, the yield was 88–98%. 
Compound 3 was converted to carbothioamides 4a,b 
by treatment with benzylisothiocyanate and ethyliso-
thiocyanate, respectively (Scheme 1). Again, the use of 
microwave irradiation was superior to the conventional 
synthesis. Condensation of compounds 4a,b with 4-chlo-
rophenacyl bromide in ethanolic solution furnished the 
corresponding thiazoles 5a,b (Scheme 2). Again, the 
microwave method was preferred. The remaining prepa-
rations shown in Schemes 2 and 3 also benefited from the 
use of the microwave irradiation methodology. Triazoles 
6a,b were obtained by intramolecular cyclization of com-
pounds 4a,b. The aim was to introduce the 1,2,4-triazole 
nucleus to the nalidixic acid skeleton because it is known 
that more efficacious antibacterial compounds can be 
designed by joining two biologically active components 
together into a single molecular framework [34–38]. The 
synthesis of carbohydrazide 7 was performed by the reac-






a: R = Bn











































Scheme 2 Reactions and conditions. i: EtOH, ClC6H4COCH2Br, CH3COONa, reflux for 54 h (5a) or EtOH, C2H5Br, CH3COONa, reflux for 45 h (5b) 
or MW irradiation; ii: 2 N NaOH in EtOH/H2O, 16 h (6a) or 14 h (6b) reflux or MW irradiation; iii: BrCH2COOEt in EtOH, CH3COONa, 24 h reflux 





















4a: R = Bn
4b: R = Et
O O O O
Scheme 1 Reactions and conditions. i: H2SO4, EtOH, 22 h reflux or MW irradiation; ii: EtOH, H2NNH2, 6 h reflux or MW irradiation; iii: CH2Cl2, 
PhCH2NCS or EtNCS, 24 h room temprature or MW irradiation.
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solution, while the cyclization of 4a in an acidic medium 
yielded a 1,3,4-thiadiazole 8.
Mannich bases are physiologically reactive agents 
[39–41]. Mannich bases 9–15 were obtained by treatment 
of compounds 6a,b with formaldehyde and several bio-
logically active amines (Scheme 3) [6, 8, 34, 42, 43]. Three 
different methods were used for the Mannich reactions. 
These were a conventional method in the absence of a cat-
alyst, a conventional method in the presence of a catalyst, 
and microwave irradiation-assisted synthesis. The clas-
sical heating in the absence of any catalyst furnished the 
desired products in low-yield after 24 h. The same products 
were obtained in the yields of 53–97% at room temperature 
after 5 h in the presence of InCl3 or p-toluenesulfonic acid 
as a Brønsted-Lowry acid catalyst. In the microwave irradi-
ation-assisted method the temperature was held constant 
at 50oC, the reaction time was 5 min and the Mannich bases 
were obtained in yields of 43–99%. Thus, microwave irra-
diation provided more efficient and green way to Mannich 
products and a relatively higher yield.
Antimicrobial activity
All synthesized compounds were screened for their anti-
microbial activity. Compounds 2, 3, 4a,b, 5a,b, 6a,b, 7, 
and 8 are active against some of the test microorganisms 
with the minimal inhibition concentration (MIC) values in 
the range of 0.49–500 μg/mL (Table 1). Compounds 4a,b 
and 6a,b are exceptionally active against Escherichia coli 
(E. coli), Gram-negative bacteria. Mannich bases 9–15 
show good-to-moderate activity against some of the test 
microorganisms. Among these, compounds 11a,b with 
a  β-lactam nucleus attached to nalidixic acid skeleton 
display remarkable antimicrobial activities against two 
Gram-positive bacteria. Compound 11a is active against 
Mycobacterium smegmatis (M. smegmatis), a nonpig-
mented rapidly growing mycobacterium with the MIC 
value  < 1 μg/mL, which is better than that for standard 
drug streptomycin. Compound 11b is active against Ente-
rococcus faecalis (E. faecalis), for which the MIC value of 
6 μg/mL is better than that for the reference drug ampicil-
lin. Exceptional activity can be observed for some other 
Mannich bases (Table 1).
Conclusions
Several biologically active hybrid compounds containing 
a nalidixic acid moiety were obtained. The antimicrobial 
screening showed that compounds containing norfloxa-
cine, ciprofloxacine or 7-aminocephalosporanic acid 
















































































a: R = Bn
b: R = Et
Scheme 3 Conditions: amine, CH2O in DMSO (see Experimental). The amines: i, morpholine; ii, thiomorpholine; iii, 7-aminocephalospo-
ranic acid; iv, norfloxacin; v, ciprofloxacin; vi, 1-phenylpiperazine; vii, tryptamine.
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compounds are more active against E. coli and M. smegma-
tis than the reference drug ampicillin and streptomycin.
Experimental
All chemicals were purchased from Fluka Chemie AG (Buchs, 
 Switzerland) and used without further purification. Melting points 
were determined in open capillaries on a Büchi B-540 melting point 
apparatus and are uncorrected. Reactions were monitored by thin layer 
chromatography (TLC) on silica gel using 60 F254 aluminum sheets. The 
mobile phase was ethyl acetate/diethyl ether (1:1) and detection was 
under UV light. FT-IR spectra were recorded using a Perkin Elmer 1600 
series FT-IR spectrometer. 1H NMR and 13C NMR spectra were registered 
in DMSO-d6 on a Bruker Avene II 400 MHz NMR spectrometer (400 MHz 
for 1H and 100 MHz for 13C). The elemental analysis was performed on 
a Costech Elemental Combustion System CHNS-O elemental analyzer.
Ethyl 1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyri-
dine-3-carboxylate (2)
Method 1 A solution of nalidixic acid (1, 2.31 g, 0.01 mol) and con-
centrated sulfuric acid (4 drops) in ethanol was heated under reflux 
for 22 h, then cooled to room temperature and concentrated under 
reduced pressure. The resultant white residue of 2 was crystallized 
from ethanol.
Method 2 A solution of compound 1 (1 mmol) and sulfuric acid 
(4 drops) in ethanol was microwave irradiated in a closed vessel 
at 100°C for 15 min and then poured into ice water. The resultant 
solid product 2 was collected by filtration and crystallized from 
ethanol.
Yield 76% (method 1); yield 88% (method 2); mp 207–208°C; IR 
(υmax, cm-1): 3072, 2980, 1720, 1683, 1616; 1H NMR: δ 1.3 (t, 3H J  =  7.2 
Hz), 1.4 (t, 3H, J  =  6.9 Hz), 2.6 (s, 3H), 4.2 (q, 2H, J  =  6.9 Hz,), 4.5 (q, 
2H, J  =  7.2 Hz), 7.4 (d, 1H, J  =  8.1 Hz,), 8.4 (d, 1H, J  =  8.1 Hz), 8.8 (s, 1H); 
13C NMR: δ 14.3, 23.6, 27.9, 41.1, 44.5, 110.8, 118.2, 125.6, 136.2, 148.9, 
154.6, 148.1, 162.2, 176.3. Anal. Calcd for C14H16N2O3: C, 64.60; H, 6.20; 
N, 10.76. Found: C, 64.25; H, 5.93; N, 10.41.
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-
3-carbohydrazide (3)
Method 1 A solution of compound 2 (2.60 g, 0.01 mol) and hydra-
zine hydrate (1.46 mL, 0.03 mol) in ethanol was heated under reflux 
for 20 h, then cooled and kept in the refrigerator for 12 h. The result-
ant solid was collected by filtration and crystallized from ethanol.
Table 1 Antimicrobial activity of the compounds.
Comp. Minimal inhibition concentration (μg/mL)
Ec Yp Pa Sa Ef Bc Ms Ca Sc
2 3.9 15.6 – – – 125 – 250 500
3 1.9 3.9 125 62.5 125 31.3 – 62.5 62.5
4a 0.49 7.81 500 31.25 – 7.81 62.5 15.65 15.65
4b 0.49 7.81 – 125 125 15.65 62.5 31.25 15.65
5a 7.8 3.9 – – – 78 – – –
5b 7.8 31.25 – – – 39 – – –
6a 0.98 7.81 – 125 – 31.25 – 250 –
6b 0.98 3.91 125 62.5 – 31.25 62.5 – –
7 7.8 31.25 – – 156 39 – – –
8 7.8 3.9 – – 312.5  > 1000 125 78 39
9a 7.8 31.25 – – – 39 – – –
9b 3.9 62.5 156 – –  > 1000 62.5 – –
10a 15.6 3.9 – – – 625 – – 156
10b 3.9 62.5 156 – 312.5  > 1000 – – –
11a 125 7.8 – – 156  > 1000  < 1 – 312.5
11b 15.6 31.25 156 – 6 39 – – –
12a  < 1 3.9 9.7 78 9.7 19 1.9 – 156
12b  < 1 3.9 9.7 – 9.7 19 1.9 – –
13a  < 1  < 1 9.7 9.7 – 9.7  < 1 – 156
13b  < 1  < 1 9.7 – 9.7 9.7  < 1 – –
14 7.8 3.9 – – – 156 – – –
15 7.8 62.5 – – – 39 – – 312.5
Amp 10 32  > 128 35 10 15
Strep 4
Flu  < 8  < 8
Ec, E. coli ATCC 35218; Yp, Y. pseudotuberculosis ATCC 911; Pa, P. aeruginosa ATCC 10145; Sa, S. aureus ATCC 25923; Ef, E. faecalis ATCC 
29212; Bc, B. cereus 709 Roma; Ms, M. smegmatis ATCC607; Ca, C. albicans ATCC 60193; Sc, S. cerevisiae RSKK 251; Amp, ampicillin; Strep, 
 streptomycin; Flu, fluconazole; (–), no activity at test concentrations.
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Method 2 A solution of compound 2 (1 mmol) and hydrazine 
hydrate (3 mmol) in ethanol was microwave-irradiated in a closed 
vessel at 100°C for 15 min. After the completion of the reaction, as 
monitored by TLC, the mixture was concentrated and the residue was 
crystallized from ethanol.
Yield 75% (method 1); yield 98% (method 2); mp 163–165°C; IR 
(υmax, cm-1): 3316, 3222, 3033, 2958, 1685, 1604; 1H NMR: δ 1.32 (s, 3H), 
2.60 (s, 3H), 4.51 (s, 2H), 7.40 (s, 1H), 8.42 (s, 1H), 8.94 (s, 1H), 10.50 (s, 
2H), 12.50 (s, 1H); 13C NMR: δ 14.3, 24.8, 40.1, 111.6, 119.4, 122.5, 135.8, 
147.9, 153.6, 147.2, 163.1, 175.8. Anal. Calcd for C12H14N4O2: C, 58.53; H, 
5.73; N, 22.75. Found: C, 58.40; H, 5.93; N, 22.48.
General synthesis of compounds 4a,b
Method 1 To a solution of compound 3 (2.46 g, 0.01 mol) in dichlo-
romethane, benzyl isothiocyanate (for 4a, 2.46 g, 0.01 mol) or ethyl 
isothiocyanate (for 4b, 1.75 g, 0.02 mol), was added and the mixture 
was stirred at room temperature for 24  h and then concentrated 
under reduced pressure. The residue was crystallized from ethanol 
(4a) or from dimethyl sulfoxide/water (1:3) (4b).
Method 2 A mixture of compound 3 (1 mmol) and the correspond-
ing isothiocyanate (1 mmol) in ethanol was irradiated in a closed ves-
sel with the pressure control at 100°C for 10 min. After cooling the 
mixture was poured into ice water and the resultant solid was crystal-
lized from an appropriate solvent.
N-Benzyl-2-[(1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthy-
ridin-3-yl)carbonyl]hydrazinecarbothioamide (4a) Yield 80% 
(method 1); yield 98% (method 2); mp 197–200°C; IR (υmax, cm-1): 3137, 
3062, 2974, 1649, 1541, 1187; 1H NMR: δ 1.40 (t, 3H, J  =  8.0 Hz), 2.71 
(brs, 3H), 4.73 (d, 2H, J  =  4.0 Hz), 4.94 (s, 2H), 7.29 (d, 1H, J  =  8.0 Hz), 
7.31–7.38 (m, 5H), 7.42 (d, 1H, J  =  8.0 Hz), 8.58 (q, 1H, J  =  8.0 Hz), 9.04 
(s, 1H), 9.18 (s, 1H), 09.47 (s, 1H); 13C NMR: δ 15.5, 25.5, 46.6, 48.5, 119.1, 
122.6, 123.4, 127.6, 127.7, 128.7, 129.3, 136.5, 148.6, 163.9, 165.1, 166.1, 
150.0, 175.9, 178.5, 183.1. Anal. Calcd for C20H21N5O2S: C, 60.74; H, 5.35; 
N, 17.71. Found: C, 60.40; H, 5.83; N, 17.48.
N-Ethyl-2-[(1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyri-
din-3-yl)carbonyl]hydrazinecarbothioamide (4b) Yield 75% 
(method 1); yield 85% (method 2); mp 180–182°C; IR (υmax, cm-1): 3144, 
3058, 2986, 1679, 1541, 1189; 1H NMR: δ 1.07 (t, 3H, J  =  8.0 Hz), 1.39 (t, 
3H, J  =  8.0 Hz), 2.69 (brs, 3H), 3.41 (brs, 2H), 4.57 (q, 2H, J  =  8.0 Hz), 
7.44–7.47 (m, 4H), 7.56 (d, 1H, J  =  8.0 Hz), 7.92 (brs, 2H), 8.53 (q, 1H, J  =  
8.0 Hz), 9.00 (s, 1H), 9.15 (s, 1H), 10.54 (s, 1H); 13C NMR: δ 14.8, 15.5, 
25.5, 46.4, 47.2, 121.8, 123.0, 136.3, 148.5, 163.9, 165.1, 149.9, 175.8, 178.5, 
182.1. Anal. Calcd for C15H19N5O2S: C, 54.04; H, 5.74; N, 21.01. Found: C, 
54.40; H, 5.93; N, 21.10.
General synthesis of compounds 5a,b
Method 1 4-Chlorophenacyl bromide (2.33 g, 0.01 mol) and sodium 
acetate (4.1 g, 0.05 mol) were added to the solution of compound 4a 
(3.95 g, 0.01 mol, for 5a) or compound 4b (3.33 g, 0.01 mol, for 5b) 
in ethanol and the mixture was heated under reflux for 54 h (for 5a) 
or 45 h (for 5b), as monitored by TLC. Then, the mixture was cooled 
to room temperature and concentrated under reduced pressure. The 
resultant solid was filtered, washed with water and crystallized from 
dimethyl sulfoxide/water (1:3).
Method 2 A solution of 4-chlorophenacyl bromide (1 mmol), 
sodium acetate (5 mmol), compound 4a (1 mmol) or compound 4b 
(1 mmol) in ethanol was microwave-irradiated in a closed vessel at 
150°C for 15 min. After completion of the reaction, as monitored by 
TLC, the mixture was poured into ice water. The crude product was 
filtered and crystallized from dimethyl sulfoxide/water (1:3).
N′-[3-Benzyl-5-(4-chlorophenyl)-1,3-thiazol-2(3H)-ylidene]-
1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carbohydrazide (5a) Yield 65% (method 1); yield 80% (method 
2); mp 175–177°C; IR (υmax, cm-1): 3043, 3079, 2980, 1716, 1521, 1129; 
1H NMR: δ 1.41 (brs, 3H), 2.67 (t, 3H, J  =  8.0 Hz), 4.24 (brs, 2H, 4.41 (q, 
2H, J  =  8.0 Hz), 5.03 (s, 1H), 7.05 (d, 1H, J  =  8.0 Hz), 7.17–7.63 (m, 9H), 
7.62 (d, 1H, J  =  8.0 Hz), 7.98 (brs, 1H), 9.17 (s, 1H); 13C NMR: δ 14.7, 25.5, 
43.6, 47.3, 110.0, 117.2, 123.1, 127.8, 128.3, 129.5, 130.2, 130.3, 135.4, 136.1, 
136.3, 140.3, 147.6, 148.1, 160.0, 166.2, 149.8, 166.8, 168.8, 176.1, 178.6. 
Anal. Calcd for C28H24ClN5O2S: C, 65.45; H, 4.56; N, 13.21. Found: C, 
65.31; H, 4.78; N, 13.01.
N′-[5-(4-Chlorophenyl)-3-ethyl-1,3-thiazol-2(3H)-ylidene]-
1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carbohydrazide (5b) Yield 70% (method 1); yield 87% (method 2); 
mp 192–193°C; IR (υmax, cm-1): 3068, 3068, 2971, 1702, 1519; 1H NMR: 
δ 1.05 (t, 3H, J  =  8.0 Hz), 1.41 (t, 3H J  =  4.0 Hz), 2.70 (brs, 3H), 3.67 
(brs), 4.60 (q, 2H, J  =  8.0 Hz), 5.03 (s, 1H), 7.48–7.58 (m, 6H), 7.58 (brs, 
1H), 9.18 (s, 1H); 13C NMR: δ 13.3, 15.5, 25.5, 46.6, 47.3, 98.9, 109.1, 119.5, 
120.0, 121.0, 123.1, 129.4, 129.5, 130.1, 131.0, 136.1, 148.8, 159.9, 150.1, 
163.8, 166.0, 171.6, 178.6. Anal. Calcd for C23H22ClN5O2S: C, 59.03; H, 
4.74; N, 14.97. Found: C, 59.33; H, 4.38; N, 14.69.
General synthesis of compounds 6a,b
Method 1 A solution of carbothioamide 4a (3.95 g, 0.01 mol, for 6a) 
or 4b (3.33 g, 0.01 mol, for 6b) in ethanol/water (1:1) was heated under 
reflux in the presence of 2 N NaOH for 16 h (for 6a) or 14 h (for 6b) with 
the progress of the reaction monitored by TLC. Then, the solution was 
cooled to room temperature and acidified to pH 7 with 37% HCl. The 
precipitate formed was filtered off, washed with water, and crystal-
lized from methanol (for 6a) or ethanol /water (1:3) (for 6b).
Method 2 A mixture of compound 4a or 4b (1 mmol) and 2N NaOH 
(2 mmol) in ethanol (10 mL) was microwave-irradiated in a closed 
vessel at 150°C for 4 min with the progress of the reaction monitored 
by TLC. Then the resulting solution was cooled to room temperature 
and acidified to pH 5 with 37% HCl. The precipitate formed was fil-
tered off, washed with water, and crystallized from an appropriate 
solvent indicated above.
3-(4-Benzyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-
1-ethyl-7-methyl-1,8-naphthyridin-4(1H)-one (6a) Yield 63% 
(method 1); yield 86% (method 2); mp  > 270°C; IR (υmax, cm-1): 3061, 
2985, 2959, 1717, 1517, 1128; 1H NMR: δ 1.17 (s, 3H), 2.50 (s, 3H), 4.33 
(brs, 2H), 5.25 (s, 2H), 7.13–7.33 (m, 7H), 8.34 (s, 1H), 9.16 (s, 1H); 13C 
NMR: δ 15.4, 25.5, 45.6, 47.3, 109.2, 118.8, 121.6, 123.1, 127.2, 127.9, 128.8, 
136.1, 136.9, 146.5, 148.8, 163.7, 150.0, 166.1, 174.7, 178.5. Anal. Calcd for 
C20H19N5OS: C, 63.64; H, 5.07; N, 18.55. Found: C, 63.28; H, 5.38; N, 18.89.
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1-Ethyl-3-(4-ethyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-7-
methyl-1,8-naphthyridin-4(1H)-one (6b) Yield 67% (method 1); 
yield 88% (method 2); mp 216-218°C; IR (υmax, cm-1): 3090, 2988, 2957, 
1717 2, 1537, 1130; 1H NMR: δ 1.14 (t, 3H, J  =  8.0 Hz), 1.41 (t, 3H, J  =  8.0 
Hz), 2.66 (s, 3H), 3.93 (q, 2H, J  =  8.0 Hz), 4.49 (q, 2H, J  =  8.0 Hz), 7.44–
7.61 (m, 2H), 8.61 (d, 1H, J  =  8.0 Hz), 9.19 (s, 1H); 13C NMR: δ 13.8, 15.5, 
25.5, 45.9, 47.3, 108.8, 119.5, 121.9, 136.2, 149.1, 163.6, 148.5, 167.1, 174.9, 
178.6. Anal. Calcd for C15H17N5OS: C, 57.12; H, 5.43; N, 22.21. Found: C, 




Method 1 Ethyl bromoacetate (1.28 mL, 0.01 mol) and sodium ace-
tate (4.1 g, 0.05 mol) were added to the solution of compound 4a 
(3.95 g, 0.01 mol) in ethanol and the mixture was heated under reflux 
for 24 h. Then, the mixture was cooled to room temperature and con-
centrated under reduced pressure. The residue was filtered, washed 
with water, and crystallized from dimethyl sulfoxide/water (1:3).
Method 2 A mixture of compound 4a (1 mmol), ethyl bromoacetate 
(1 mmol) and sodium acetate (5 mmol) in ethanol was irradiated in 
a closed vessel at 150°C for 13 min with the progress of the reaction 
monitored by TLC. After the completion of the reaction, the mixture 
was poured into ice water and the resultant precipitate was filtered 
and crystallized from dimethyl sulfoxide/water (1:3).
Yield 55% (method 1); yield 76% (method 2); mp 230–232°C; IR 
(υmax, cm-1): 3031, 1698 2, 1495, 1127; 1H NMR: δ 1.42 (s, 3H), 4.23 (s, 2H), 
4.63 (t, 3H, J  =  8.0 Hz), 4.79 (s, 2H), 7.26-742 (m, 7H), 8.59 (t, 1H, J  =  
8.0 Hz), 9.03 (s, 1H); 13C NMR: δ 15.5, 25.4, 40.4, 44.1, 45.9, 109.1, 118.8, 
123.1, 127.0, 127.3, 127.6, 127.7, 128.0, 136.1, 136.3, 148.8, 160.1, 150.1, 
165.1, 166.1, 172.2, 178.6. Anal. Calcd for C22H21N5O3S: C, 60.67; H, 4.86; 
N, 16.08. Found: C, 60.32; H, 4.49 H; N, 16.28.
3-[5-(Benzylamino)-4,5-dihydro-1,3,4-thiadiazol-2-yl]-
1-ethyl-7-methyl-1,8-naphthyridin-4(1H)-one (8)
Method 1 A solution of carbothioamide 4a (3.95 g, 0.01 mol) in con-
centrated sulfuric acid (11 mL, 0.20 mol) was stirred for 15 min at 0°C, 
then allowed to reach room temperature and stirred for an additional 
3 h. The solution was poured into ice-cold water and made alkaline 
to pH 7 with ammonia. The precipitated product was filtered, washed 
with water, and crystallized from ethanol/water (1:3).
Method 2 A solution of compound 4a (1 mmol) in concentrated sul-
furic acid (1.5 mL) was irradiated in a closed vessel at 50°C for 4 min 
with the progress of the reaction monitored by TLC. After completion 
of the reaction, the mixture was poured into ice water and the result-
ant crude product was collected by filtration and crystallized from 
ethanol/water (1:3).
Yield 74% (method 1); yield 83% (method 2); mp 193–195°C; IR 
(υmax, cm-1): 3197, 1715, 1518, 1080; 1H NMR: δ 1.41 (s, 3H), 2.67 (t, 3H, 
J  =  8.0 Hz), 3.45 (brs, 2H), 4.63 (brs, 2H), 7.16–7.56 (m, 7H), 8.55 (brs, 
1H), 9.16 (s, 1H); 13C NMR: δ 15.5, 25.5, 46.6, 47.9, 109.1, 119.9, 123.1, 127.3, 
127.7, 128.6, 129.3, 136.0, 142.6, 148.9, 163.0, 165.1, 149.9, 166.0, 172.8, 
178.5. Anal. Calcd for C20H19N5O2: C, 66.47; H, 5.30; N, 19.38. Found: C, 
66.32; H, 4.89; N, 16.08.
General synthesis of compounds 9–13 (a,b)
Method 1 To a solution of compound 6a or 6b (0,01 mol) in dime-
thyl sulfoxide (10 mL), morpholine (for 9a and 9b, 0.87 mL, 0.01 mol) 
or thiomorpholine (for 10a and 10b, 0.94 mL, 0.01 mol) or 7-amino-
cephalosporanic acid (for 11a and 11b, 2.72 g, 0.01 mol) or norfloxacin 
(for 12a and 12b, 3.19 g, 0.01 mol) or ciprofloxacin (for 13a and 13b, 
3.31 g, 0.01 mol) was added in the presence of formaldehyde (37%, 
3.72 mL, 0.05 mol) and the mixture was stirred at room temperature 
for 22 h. The solution was poured into ice-cold water and the result-
ant solid was crystallized from ethanol/water (1:3) (for 9a,b, 10a,b), 
from ethyl acetate (for 11a,b) and from dimethyl sulfoxide/water (1:3) 
(for 12a,b, 13a,b).
Method 2 To a solution of compound 6a,b (1 mmol) in dimethyl 
sulfoxide (10 mL), morpholine (for 9a and 9b, 1 mmol) or thiomor-
pholine (for 10a and 10b, 1 mmol) or 7-aminocephalosporanic acid 
(for 11a and 11b, 1 mmol) or norfloxacin (for 12a and 12b, 1 mmol) or 
ciprofloxacin (for 13a and 13b, 1 mmol) was added in the presence 
of formaldehyde (5 mmol) and the mixture was stirred at room tem-
perature for 15 min. Then, a catalytic amount of a suitable catalyst 
(InCl3 or p-TsOH) was added and the stirring was continued for an 
additional 5 h. The mixture was poured into ice water and a resultant 
solid was crystallized from an appropriate solvent indicated above.
Method 3 The mixture, obtained as described above for method 2, 
was irradiated at 50°C in a microwave oven for 5 min with the pro-
gress of the reaction monitored by TLC. After cooling the solution was 
poured into ice water and the resultant precipitate was filtered off 
and crystallized from an appropriate solvent indicated above.
3-[4-Benzyl-1-(morpholin-4-ylmethyl)-5-thioxo-4,5-dihydro-
1H-1,2,4-triazol-3-yl]-1-ethyl-7-methyl-1,8-naphthyridin-4(1H)-
one (9a) Yield 73% (method 1); yield 75% (method 2, InCl3); yield 
77% (method 2, p-TsOH); yield 90% (method 3); mp 106–108°C; IR 
(υmax, cm-1): 1629, 1498, 1152, 1078; 1H NMR: δ 1.19 (t, 3H, J  =  4.0 Hz), 
2.56 (s, 4H), 2.73 (s, 3H), 3.36 (s, 4H), 4.37 (brs, 2H), 5.14 (s, 2H), 5.31 
(s, 2H), 6.97 (brs, 2H), 7.15–7.30 (m, 5H), 7.46 (d, 2H J  =  8.0 Hz), 8.52 (s, 
1H); 13C NMR: δ 15.4, 25.3, 45.7, 48.6, 50.8, 66.6, 69.6, 108.6, 119.3, 121.8, 
127.5, 127.8, 128.0, 128.8, 136.2, 136.3, 147.6, 148.8, 146.5, 163.7, 169.1, 
174.7. Anal. Calcd for C25H28N6O2S: C, 63.00; H, 5.92; N, 17.63. Found: C, 
63.28; H, 6.01; N, 17.32.
1-Ethyl-3-[4-ethyl-1-(morpholin-4-ylmethyl)-5-thioxo-4,5-di-
hydro-1H-1,2,4-triazol-3-yl]-7-methyl-1,8-naphthyridin-4(1H)-
one (9b) Yield 65% (methods 1 and 2); yield 66% (method 2, 
p-TsOH); yield 85% (method 3); mp 209–210°C; IR (υmax, cm-1): 1710, 
1519, 1162, 1081; 1H NMR: δ 1.17 (s, 3H), 1.40 (s, 3H), 2.68 (s, 3H), 3.35 
(s, 4H), 3.57 (s, 4H), 3.95 (brs, 2H), 4.49 (s, 2H), 5.06 (s, 2H), 7.46 (d, 
2H, J  =  8.0 Hz), 8.46 (brs, 1H), 8.65 (s, 1H); 13C NMR: δ 13.6, 15.4, 25.4, 
46.0, 50.8, 52.0, 66.5, 69.1, 108.2, 119.4, 121.6, 136.2, 147.2, 149.1, 146.8, 
163.6, 168.1, 178.5. Anal. Calcd for C20H26N6O2S: C, 57.95; H, 6.32; N, 
20.27. Found: C, 57.71; H, 6.01; N, 20.01.
3-[4-Benzyl-1-(thiomorpholin-4-ylmethyl)-5-thioxo-4,5-dihy-
dro-1H-1,2,4-triazol-3-yl]-1-ethyl-7-methyl-1,8-naphthyridin-
4(1H)-one (10a) Yield 40% (method 1); yield 53% (method 2, InCl3 
or p-TsOH); yield 47% (method 3); mp 100–102°C; IR (υmax, cm-1): 
3069, 2957, 1627, 1496, 1131; 1H NMR: δ 1.41 (t, 3H J  =  8.0 Hz), 2.61 (s, 
4H), 2.71 (s, 3H), 3.36 (s, 4H), 4.29 (q, 2H, J  =  8.0 Hz), 4.64 (brs, 2H), 
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5.27 (s, 2H), 6.45 (brs, 1H), 7.00–7.95 (m, 7H), 8.51 (s, 1H); 13C NMR: δ 
15.3, 25.3, 40.7, 45.7, 48.3, 52.3, 70.0, 108.7, 111.3, 117.8, 121.8, 127.2, 127.5, 
127.7, 128.8, 132.9, 136.2, 136.2, 147.6, 146.5, 148.8, 163.7, 174.7. Anal. 




one (10b) Yield 35% (method 1); yield 55% (method 2, InCl3); yield 
56% (method 2, p-TsOH); yield 43% (method 3); mp 192–193°C; IR 
(υmax, cm-1): 3087, 2980, 1710, 1518, 1128; 1H NMR: δ 1.17 (s, 3H), 1.40 
(s, 3H), 2.67 (s, 3H), 2.99 (s, 4H), 3.34 (s, 4H), 3.95 (s, 2H), 4.49 (s, 2H), 
5.08 (s, 2H), 7.45 (d, 2H, J  =  8.0 Hz), 8.48 (brs, 1H), 8.63 (s, 1H); 13C 
NMR: δ 13.6, 15.5, 25.3, 46.0, 50.6, 52.8, 66.6, 70.4, 108.2, 119.4, 121.6, 
136.2, 147.2, 149.1, 146.8, 163.6, 167.9, 178.5. Anal. Calcd for C20H26N6OS2: 




oct-2-ene-2-carboxylic acid (11a) Yield 55% (method 1); yield 64% 
(method 2, InCl3); yield 60% (method 2, p-TsOH); yield 74% (method 
3); mp 148–150°C; IR (υmax, cm-1): 3305, 3057, 1771, 1715 4, 1556, 1130; 1H 
NMR: δ 1.41 (t, 3H, J  =  8.0 Hz), 1.91 (s, 3H), 2.73 (brs, 3H), 3.43 (q, 2H, J  =  
4.0 Hz), 3.96 (s, 1H), 4.34 (brs, 2H), 5.02 (d, 2H, J  =  8.0 Hz), 5.29 (brs, 2H), 
5.45 (s, 2H), 5.54 (s, 1H), 7.04-7.95 (m, 7H), 8.58 (s, 1H), 9.17 (s, 1H), 14.04 
(s, 1H); 13C NMR: δ 14.7, 22.01, 26.3, 27.0, 45.7, 47.3, 59.2, 63.2, 68.1, 71.3, 
108.9, 109.1, 119.4, 123.0, 125.0, 127.3, 127.9, 128.8, 136.0, 136.2, 146.4, 148.8, 
148.8, 120.5, 150.0, 163.5, 163.7, 167.3, 168.1, 174.7, 178.5. Anal. Calcd for 




oct-2-ene-2-carboxylic acid (11b) Yield 58% (method 1); yield 69% 
(method 2, InCl3); yield 70% (method 2, p-TsOH); yield 81% (method 
3); mp 140–142°C; IR (υmax, cm-1): 3280, 3047, 1768, 1710 4, 1562, 1130; 1H 
NMR: δ 1.15 (t, 3H, J  =  8.0 Hz), 1.41 (t, 3H, J  =  8.0 Hz), 1.91 (s, 3H), 2.71 
(brs, 3H), 3.32 (brs, 2H), 3.92 (s, 1H), 4.47 (brs, 2H), 4.63 (brs, 2H), 5.01 
(d, 2H, J  =  8.0 Hz), 5.53 (s, 1H), 7.44 (d, 1H, J  =  8.0 Hz), 7.59 (d, 1H, J  =  8.0 
Hz), 8.60 (s, 1H), 9.16 (s, 1H), 13.82 (s, 1H); 13C NMR: δ 13.8, 15.4, 21.5, 25.5, 
27.1, 45.9, 47.3, 58.2, 64.3, 69.1), 72.0, 108.8, 109.8, 118.8, 123.1, 136.2, 148.5, 
149.1, 119.4, 150.0, 163.5, 165.1, 166.0, 167.1, 174.9, 178.6. Anal. Calcd for 




3-carboxylic acid (12a) Yield 82% (method 1); yield 92% (method 
2, InCl3); yield 91% (method 2, p-TsOH); yield 98% (method 3); mp 
200–202°C; IR (υmax, cm-1): 3451, 1720, 1562, 1130; 1H NMR: δ 1.39 (t, 
3H, J  =  8.0 Hz), 1.96 (s, 3H), 2.64 (brs, 3H), 2.98 (s, 4H), 3.39 (brs, 4H), 
4.34 (brs, 2H), 4.60 (brs, 2H), 5.25 (d, 4H, J  =  8.0 Hz), 6.53 (s, 1H), 
7.15–7.57 (m, 7H), 7.83 (brs, 1H), 8.47 (s, 1H), 8.92 (s, 1H), 14.89 (s, 1H); 
13C NMR: δ 14.8 (CH3), 15.3 (CH3), 25.5 (CH3), 44.8 (N-2CH2), 46.4 (CH2), 
47.2 (N-2CH2), 49.5, 49.9, 50.2, 106.0, 110.4, 112.3, 118.7, 119.6 and 119.7 
(d, CH, J  =  7.0 Hz), 121.8, 123.0, 126.1, 127.2 and 127.6 (d, CH, J  =  47.0 
Hz), 128.6 and 128.8 (d, CH, J  =  17.0 Hz), 135.0 (CH), 135.9 and 136.2 
(d, C, J  =  26.0 Hz), 142.3 (C), 145.9 (CH), 146.5 and 147.7 (d, C, J  =  122.0 
Hz), 151.9 and 153.6 (d, C, J  =  161.0 Hz), 165.1, 107.5, 108.4, 149.1, 149.9, 
166.6, 169.1, 174.7, 176.5, 178.5. Anal. Calcd for C37H37FN8O4S: C, 62.70; 




boxylic acid (12b) Yield 85% (method 1); yield 98% (method 2, 
InCl3); yield 92% (method 2, p-TsOH); yield 96% (method 3); mp 220–
222°C; IR (υmax, cm-1): 3372, 1710, 1517, 1130; 1H NMR: δ 1.17 (s, 3H), 1.39 
(t, 3H J  =  8.0 Hz), 1.97 (s, 3H), 2.66 (brs, 3H), 2.95 (s, 4H), 3.36 (brs, 
4H), 3.96 (s, 2H), 4.48 (brs, 2H), 4.56 (brs, 2H), 5.18 (s, 2H), 7.13 (s, 1H), 
7.42 (brs, 1H), 7.54 (brs, 1H), 7.80 (brs, 1H), 8.88 (s, 1H), 9.03 (s, 1H), 
15.27 (s, 1H); 13C NMR: δ 13.6, 14.8, 15.4, 25.5, 43.3, 45.8, 48.0, 49.5, 49.9, 
50.2, 106.2, 109.8, 110.8, 119.4 and 119.5 (d, C, J  =  15.0 Hz), 121.6 and 
122.9 (d, CH, J  =  136.0 Hz), 135.9 and 136.1 (d, CH, J  =  17.0 Hz), 137.5, 
145.8, 149.1 and 149.9 (d, C, J  =  84.0 Hz), 154.1 and 156.1 (d, C, J  =  200.0 
Hz), 163.6 and 165.1 (d, C, J  =  153.0 Hz), 107.5, 108.2, 149.2, 149.9, 166.5, 
168.1, 174.9, 176.5, 178.4. Anal. Calcd for C32H35FN8O4S: C, 59.43; H, 5.45; 




noline-3-carboxylic acid (13a) Yield 82% (method 1); yield 90% 
(method 2, InCl3); yield 97% (method 2, p-TsOH); yield 97% (method 
3); mp  > 270°C; IR (υmax, cm-1): 3300, 1716 3, 1481, 1130; 1H NMR: δ 1.18 
(s, 2H), 1.32 (s, 2H), 1.41 (t, 3H, J  =  8.0 Hz), 2.69 (brs, 3H), 2.99 (s, 4H), 
3.38 (brs, 4H), 3.83 (brs, 2H), 4.33 (d, 4H, J  =  8.0 Hz), 4.66 (brs, 1H), 
5.25 (s, 2H), 6.98 (s, 1H), 7.13–7.84 (m, 7H), 7.95 (s, 1H), 8.61 (s, 1H), 
9.01 (s, 1H), 15.15 (s, 1H); 13C NMR: δ 8.0 (2CH2), 15.3, 25.5, 36.3, 44.3 
(N-2CH2), 47.3 (N-2CH2), 48.4, 49.9, 50.2, 106.9, 118.8, 119.0 and 120.3 
(d, C, J  =  129.0 Hz), 122.7, 123.9, 127.2, 127.6, 127.9 and 127.9 (d, CH, J  =  
7.0 Hz), 128.7 and 128.8 (d, CH, J  =  6.0 Hz), 136.0, 136.1 (2C), 138.5 and 
139.5 (d, C, J  =  100.0 Hz), 144.5, 146.1 and 147.7 (d, C, J  =  162.0 Hz), 
148.6, 162.8 and 163.7 (d, C, J  =  88.0 Hz)], 107.2, 118.6, 148.3, 148.8, 
166.4, 169.1, 174.7, 176.7, 178.5. Anal. Calcd for C37H37FN8O4S: C, 63.32; 




boxylic acid (13b) Yield 79% (method 1); yield 85% (method 2, InCl3); 
yield 88% (method 2, p-TsOH);. yield 95% (method 3); mp 228–230°C; 
IR (υmax, cm-1): 3456, 1710 3, 1558, 1159; 1H NMR: δ 1.18 (s, 2H), 1.32 (s, 2H), 
1.40 (t, 3H, J  =  8.0 Hz), 1.96 (s, 3H), 2.69 (brs, 3H), 2.97 (s, 4H), 3.33 (brs, 
4H), 3.82 (brs, 2H), 4.49 (d, 4H, J  =  8.0 Hz), 4.64 (brs, 1H), 5.25 (s, 2H), 
7.44–7.79 (m, 4H), 8.61 (s, 1H), 9.05 (s, 1H), 15.08 (s, 1H); 13C NMR: δ 8.0, 
15.3, 25.4, 27.7, 36.4, 43.8, 45.9, 47.2, 48.8, 49.7, 51.2, 105.9, 109.8, 119.0 and 
119.6 (d, C, J  =  50.0 Hz), 121.7, 123.9, 125.9 and 125.9 (d, CH, J  =  7.0 Hz), 
128.1 and 128.8 (d, CH, J  =  76.0 Hz), 135.0, 139.5 and 141.5 (d, C, J  =  200.0 
Hz), 146.1 and 148.6 (d, C, J  =  253.0 Hz), 161.9 and 162.6 (d, C, J  =  72.0 
Hz), 107.7, 108.6, 143.6, 149.1, 166.2, 169.1, 173.9, 175.8, 178.3. Anal. Calcd for 
C33H35FN8O4S: C, 60.17; H, 5.36; N, 17.01. Found: C, 60.31; H, 5.15; N, 17.37.
General synthesis of compounds 14 and 15
Method 1 To a solution of compound 6a (0.01 mol) in dimethyl sulf-
oxide, 1-phenylpiperazine (for 14, 1.52 mL, 0.01 mol) or tryptamine 
(for 15, 1.60 g, 0.01 mol) was added in the presence of formaldehyde 
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(37%, 3.72 mL, 0.05 mol) and the mixture was stirred at room tem-
perature for 24 h, then poured into ice-cold water. The resultant pre-
cipitate was crystallized from ethanol/water (1:3).
Method 2 To a solution of compound 6a (1 mmol) in dimethyl sulfox-
ide, 1-phenylpiperazine (for 14, 1 mmol) or tryptamine (for 15, 1 mmol) 
was added in the presence of formaldehyde (5 mmol) and the mixture 
was stirred at room temperature for 15 min. Then, a catalytic amount 
of a catalyst (InCl3 or p-TsOH) was added and the stirring was contin-
ued for an additional 5 h. The mixture was poured into ice water and 
the resultant precipitate was crystallized from ethanol/water (1:3).
Method 3 A solution, prepared as described above, was irradiated 
at 50oC in the microwave oven for 5 min, then cooled to room temper-
ature and poured into ice water. The resultant precipitate was filtered 
off and crystallized from ethanol/water (1:3).
3-{4-Benzyl-1-[(4-phenylpiperazin-1-yl)methyl]-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-3-yl}-1-ethyl-7-methyl-1,8-naphthyridin-
4(1H)-one (14) Yield 74% (method 1); yield 78% (method 2, InCl3); 
yield 80% (method 2, p-TsOH); yield 93% (method 3); mp 106–108°C; 
IR (υmax, cm-1): 1726, 1495, 1155; 1H NMR: δ 1.37 (t, 3H, J  =  8.0 Hz), 2.59 
(s, 3H), 2.92 (s, 4H), 3.13 (brs, 4H), 4.35 (brs, 2H), 5.23 (s, 2H), 5.32 (s, 
2H), 6.77 (brs, 1H), 6.95 (d, 3H, J  =  8.0 Hz), 7.15–7.29 (m, 7H), 7.45 (brs, 
1H), 7.95 (s, 1H); 13C NMR: δ 15.4, 25.3, 47.3, 48.3, 48.8, 50.4, 69.4, 108.6, 
116.1, 119.3, 119.4, 121.8, 127.4, 127.5, 127.8, 127.9, 128.6, 128.7, 128.8, 129.3, 
136.2, 136.3, 147.6, 148.8, 151.5, 146.5, 163.7, 169.1, 174.7. Anal. Calcd for 
C31H33N7OS: C, 67.49; H, 6.03; N, 17.77. Found: C, 67.28; H, 6.06; N, 17.98.
3-[4-Benzyl-1-({[2-(1H-indol-3-yl)ethyl]amino}methyl)-5-thioxo-
4,5-dihydro-1H-1,2,4-triazol-3-yl]-1-ethyl-7-methyl-1,8-naphthy-
ridin-4(1H)-one (15) Yield 71% (method 1); yield 80% (method 2, 
InCl3), yield 82% (method 2, p-TsOH); yield 99% (method 3); mp 163–
165°C; IR (υmax, cm-1): 3029 2, 1710, 1503, 1155; 1H NMR: δ 1.20 (t, 3H, J  =  
8.0 Hz), 2.66 (s, 3H), 4.36 (t, 2H, J  =  8.0 Hz), 4.64 (t, 2H, J  =  8.0 Hz), 
5.12 (s, 2H), 5.30 (s, 2H), 5.54 (s, 2H), 6.99 (brs, 3H), 7.14–7.31 (m, 7H), 
7.48 (d, 2H, J  =  8.0 Hz), 8.54 (s, 1H), 9.01 (s, 1H), 9.21 (s, 1H), 14.93 (s, 
1H); 13C NMR: δ 15.3, 25.3, 25.5, 45.6, 47.3, 48.2, 71.3, 108.7, 119.3, 121.8, 
123.1, 127.6 (2CH), 128.0 (2CH), 128.8 (2CH), 136.1, 136.2 (2CH), 146.4 
(2CH), 147.9, 148.8, 152.2, 163.7, 150.1, 164.9, 167.9, 174.7. Anal. Calcd for 
C31H31N7OS: C, 67.73; H, 5.68; N, 17.84. Found: C, 67.49; H, 6.05; N, 17.97.
Antimicrobial activity
The following test microorganisms were obtained from the Hifzissi-
hha Institute of Refik Saydam (Ankara, Turkey): E. coli ATCC35218, 
Yersinia pseudotuberculosis (Y. pseudotuberculosis) ATCC911, 
Pseudomonas aeruginosa (P. aeruginosa) ATCC43288, E. faecalis 
ATCC29212, Staphylococcus aureus (S. aureus) ATCC25923, Bacil-
lus cereus (B. cereus) 709 Roma, M. smegmatis ATCC607, Candida 
albicans (C. albicans) ATCC60193, and Saccharomyces cerevisiae (S. 
cerevisia) RSKK 251. All synthesized compounds were weighed and 
dissolved in hexane to prepare a stock solution of 20.0 μg/mL. The 
antimicrobial effects of the substances were tested quantitatively 
by using double microdilution; the MIC values (μg/mL) were deter-
mined. The antibacterial and antifungal assays were performed in 
Mueller-Hinton broth (MH) (Difco, Detroit, MI, USA) at pH 7.3 and 
buffered yeast nitrogen base (Difco, Detroit, MI, USA) at pH 7.0, 
respectively. The microdilution test plates were incubated for 18–24 h 
at 35°C. Brain heart infusion broth (BHI) (Difco, Detriot, MI, USA) was 
used for M. smegmatis; incubation was for 48–72 h at 35°C [44]. Ampi-
cillin, streptomycin, and fluconazole were used as standard antibac-
terial and antifungal drugs. Dimethyl sulfoxide with a dilution of 1:10 
was used as a solvent control.
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